Cost‐effectiveness of the tandem t: Slim X2 with control‐IQ technology automated insulin delivery system in children and adolescents with type 1 diabetes in Sweden
Authors' conclusion
Initiation of CIQ use in children with type 1 diabetes is cost-saving, besides previously shown improved glycaemic control, and increased quality of life. Further investigations are needed to more fully elucidate the cost-effectiveness of these technologies in different countries with existing differences in payment models.
Study context
- Population
- Children with T1D in Sweden
- Participants
- 84 children
- Exposure
- CIQ vs MDI or continuous subcutaneous insulin infusion (CSII), in conjunction with CGM
- CIQn = 37
- MDIn = 19reference
- CSIIn = 28reference
- Outcome
- Quality adjusted life years (QALYs), cost per QALY and ICER
- Follow-up
- 10, 20 and 30-year time horizons
Methodological detailsMarkov model, four-state Markov model, probabilistic sensitivity analyses, clinical input from retrospective observational study, Data sources: retrospective observational study, local diabetes supply companies and government agencies, published literature
- Markov model
- Four-state Markov model
- Probabilistic sensitivity analyses
- Clinical input from retrospective observational study
- Data sources: retrospective observational study, local diabetes supply companies and government agencies, published literature
Main finding
As reported in the abstract
ICER · 10, 20 and 30 years
- CIQ vs MDI
- 10-year incremental cost-effectiveness ratio (ICER) −88,010.37 SEK
- CIQ vs CSII
- 10-year ICER −91,723.92 SEK
- CIQ vs MDI
- 20-year ICER −72,095.33 SEK
- CIQ vs CSII
- 20-year ICER −87,707.79 SEK
- CIQ vs MDI
- 30-year ICER −65,573.01 SEK
- CIQ vs CSII
- 30-year ICER −85,495.68 SEK
Observational data: associations, not effects.
Further findings
Probabilistic sensitivity analyses
- Probabilistic sensitivity analyses (PSA) confirmed CIQ was less costly vs MDI and CSII
Original publication
Cost‐effectiveness of the tandem t: Slim X2 with control‐IQ technology automated insulin delivery system in children and adolescents with type 1 diabetes in Sweden. Diabet Med. Published 6 September 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →